Role of COMT, 5-HT 1A, and SERT genetic polymorphisms on antidepressant response to transcranial magnetic stimulation

Depression and Anxiety

Volumn 28, Issue 7, 2011, Pages 568-573

  Malaguti, Alessia ^a   Rossini, David ^a   Lucca, Adelio ^a   Magri, Lorenzo ^a   Lorenzi, Cristina ^a   Pirovano, Adele ^a   Colombo, Christina ^a   Smeraldi, Enrico ^a   Zanardi, Raffaella ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

5 HT1A; COMT; depression; genetic; serotonin transporter; TMS

Indexed keywords

ANTIDEPRESSANT AGENT; CATECHOL METHYLTRANSFERASE; SEROTONIN 1A RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; DRUG RESISTANCE; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ALLELES; BIPOLAR DISORDER; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; OPEN READING FRAMES; PERSONALITY INVENTORY; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PSYCHOMETRICS; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 79959963903     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20815     Document Type: Article

References (59)

1. Fitzgerald PB, Hoy K, McQueen S, et al. A randomized trial of rTMS targeted with MRI based neuro-navigation in treatment-resistant depression. Neuropsychopharmacology 2009; 34: 1255-1262.
2. Padberg F, George MS,. Repetitive transcranial magnetic stimulation of the prefrontal cortex in depression. Exp Neurol 2009; 219: 2-13.
3. Baxter Jr LR, Schwartz JM, Phelps ME, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989; 46: 243-250. (Pubitemid 19078261)
4. Schutter DJ,. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. Psychol Med 2009; 39: 65-75.
5. Fregni F, Marcolin MA, Myczkowski M, et al. Predictors of antidepressant response in clinical trials of transcranial magnetic stimulation. Int J Neuropsychopharmacol 2006; 9: 641-654. (Pubitemid 46127397)
6. Lisanby SH, Husain MM, Rosenquist PB, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology 2009; 34: 522-534.
7. Zanardi R, Magri L, Rossini D, et al. Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression. Eur Neuropsychopharmacol 2007; 17: 651-657. (Pubitemid 47268754)
8. Bocchio-Chiavetto L, Miniussi C, Zanardini R, et al. 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neurosci Lett 2008; 437: 130-134.
9. Cheeran B, Talelli P, Mori F, et al. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol 2008; 586: 5717-5725.
10. Juckel G, Mendlin A, Jacobs BL,. Electrical stimulation of rat medial prefrontal cortex enhances forebrain serotonin output: implications for electroconvulsive therapy and transcranial magnetic stimulation in depression. Neuropsychopharmacology 1999; 21: 391-398. (Pubitemid 29333077)
11. 1A and NMDA binding sites by a single rapid transcranial magnetic stimulation procedure in rats. Brain Res 1999; 826: 309-312. (Pubitemid 29222948)
12. 2 receptor characteristics in rat brain. Brain Res 1999; 816: 78-83. (Pubitemid 29225425)
13. Gur E, Lerer B, Dremencov E, Newman ME,. Chronic repetitive transcranial magnetic stimulation induces subsensitivity of presynaptic serotonergic autoreceptor activity in rat brain. Neuroreport 2000; 11: 2925-2929.
14. Ikeda T, Kurosawa M, Uchikawa C, et al. Modulation of monoamine transporter expression and function by repetitive transcranial magnetic stimulation. Biochem Biophys Res Commun 2005; 327: 218-224. (Pubitemid 40051374)
15. Sibon I, Strafella AP, Gravel P, et al. Acute prefrontal cortex TMS in healthy volunteers: effects on brain (11)C-alphaMtrptrapping. Neuroimage 2007; 34: 1658-1664. (Pubitemid 46187059)
16. Heils A, Teufel A, Petris S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621-2624. (Pubitemid 26159101)
17. 1A functional promoter polymorphism with antidepressant response. Int J Psychopharmacol 2004; 7: 501-506. (Pubitemid 39648081)
18. Keck ME, Welt T, Müller MB, et al. Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. Neuropharmacology 2002; 43: 101-109. (Pubitemid 35245679)
19. Funamizu H, Ogiue-Ikeda M, Mukai H, et al. Acute repetitive transcranial magnetic stimulation reactivates dopaminergic system in lesion rats. Neurosci Lett 2005; 383: 77-81. (Pubitemid 40779959)
20. Strafella AP, Paus T, Barrett J, Dagher A,. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci 2001; 21: 157.
21. Pogarell O, Koch W, Pöpperl G, et al. Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: preliminary results of a dynamic [123I] IBZM SPECT study. J Psychiatr Res 2006; 40: 307-314. (Pubitemid 43668986)
22. Cho SS, Strafella AP,. rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. PLoS One 2009; 4: 6725.
23. Lachman HM, Papolos DF, Saito T, et al. Human catechol- O -methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243-250. (Pubitemid 26226317)
24. Szegedi A, Rujescu D, Tadic A, et al. The catechol- O -methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 2005; 5: 49-53. (Pubitemid 40220617)
25. Arias B, Catalan R, Gasto C, et al. Genetic variability in the promoter region of the serotonin transporter gene is associated with clinical remission of major depression after long term treatment with citalopram. World J Biol Psychiatry 2001; 2: 9.
26. Benedetti F, Colombo C, Pirovano A, et al. The catechol- O -methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology 2009; 203: 155-160.
27. Benedetti F, Barbini B, Bernasconi A, et al. Acute antidepressant response to sleep deprivation combined with light therapy is influenced by the catechol- O -methyltransferase Val(108/158)Met polymorphism. J Affect Disord 2001; 121: 68-72.
28. Illi A, Setälä-Soikkeli E, Kampman O, et al. Catechol- O -methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. Psychiatry Res 2010; 176: 85-87.
29. Leckman JF, Sholomskas D, Thompson WD, et al. Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch Gen Psychiatry 1982; 39: 879-883. (Pubitemid 12042853)
30. Thase ME, Rush AJ,. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58: 23-29. (Pubitemid 28011969)
31. Wassermann EM,. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol 1996; 108: 1-16.
32. Hamilton M,. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
33. Schönfeldt-Lecuona C, Lefaucheur JP, Cardenas-Morales L, et al. The value of neuronavigated rTMS for the treatment of depression. Neurophysiol Clin 2010; 40: 37-43.
34. Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508-511. (Pubitemid 28515526)
35. Lorenzi C, Serretti A, Mandelli L, et al. 5-HT 1A polymorphism and self-transcendence in mood disorders. Am J Med Genet B Neuropsychiatr Genet 2005; 137: 33-35. (Pubitemid 41076610)
36. Nakamura M, Ueno S, Sano A, Tanabe H,. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5: 32-38. (Pubitemid 30088450)
37. Rossini D, Lucca A, Zanardi R, et al. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res 2005; 137: 1-10. (Pubitemid 41550123)
38. Baeken C, De Raedt R, Van Hove C, et al. HF-rTMS treatment in medication-resistant melancholic depression: results from 18FDG-PET brain imaging. CNS Spectr 2009; 14: 439-448.
39. 1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol 2004; 7: 1-8.
40. Serretti A, Artioli P,. From molecular biology to pharmacogenetics: a review of literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology 2004; 174: 490-503. (Pubitemid 39119338)
41. 1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol 2005; 19: 166-172. (Pubitemid 40577221)
42. Hong CJ, Chen TJ, Yu YW, Tsai SJ,. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics 2006; 6: 27-33. (Pubitemid 43118308)
43. 1A receptor: signalling, desensitisation, and gene transcription. Neuropsychopharmacology 1996; 14: 19-25. (Pubitemid 26047182)
44. Perez V, Gilaberte I, Facies D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349: 1594-1597. (Pubitemid 27229140)
45. Zanardi R, Artigas A, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 1997; 17: 446-450. (Pubitemid 28389183)
46. Zanardi R, Franchini L, Gasperini M, et al. Faster onset of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol 1998; 18: 441-446. (Pubitemid 28555326)
47. 1B receptor binding parameters in rat brain membranes. Bioelectromagnetics 2006; 27: 414-422. (Pubitemid 44015489)
48. Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215-219. (Pubitemid 30053421)
49. Yoshida K, Ito K, Sato K, et al. Influence of serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 383-386. (Pubitemid 34038069)
50. Yu YW, Tsai SJ, Chen TJ, et al. Association study of serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 1115-1119. (Pubitemid 36044271)
51. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587-590.
52. Zanardi R, Benedetti F, Di Bella D, et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105-107. (Pubitemid 30056365)
53. Arias B, Serretti A, Lorenzi C, et al. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 2006; 90: 251-256. (Pubitemid 43185979)
54. Zanardi R, Serretti A, Rossini D, et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and SERTPR in delusional and non delusional depression. Biol Psychiatry 2001; 50: 323-330. (Pubitemid 32816944)
55. Durham LK, Webb SM, Milos PM, et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology 2004; 174: 525-529. (Pubitemid 39119341)
56. Serretti A, Cusin C, Rausch JL, et al. Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. Psychiatry Res 2006; 145: 61-65. (Pubitemid 44709196)
57. Anttila S, Huuhka K, Huuhka M, et al. Catechol- O -methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy. Pharmacogenomics J 2008; 8: 113-116. (Pubitemid 351411547)
58. Domschke K, Zavorotnyy M, Diemer J, et al. COMT val158met influence on electroconvulsive therapy response in major depression. Am J Med Genet B Neuropsychiatr Genet 2010; 153: 286-290.
59. Huuhka K, Anttila S, Huuhka M, et al. Dopamine 2 receptor C957T and catechol-o-methyltransferase Val158Met polymorphisms are associated with treatment response in electroconvulsive therapy. Neurosci Lett 2008; 448: 79-83.